Our blog
News from us
Welcome to the Boli blog.
Here you’ll find updates about our company and product, along with the latest scientific insights and research on GLP-1 therapies and the broader world of metabolic health.
Our goal is to share knowledge, highlight innovation, and contribute to building better care for patients worldwide.
What Happens After You Stop GLP-1 Therapy? The Rebound Risk
The rise of GLP-1 receptor agonists like semaglutide and tirzepatide has transformed obesity treatment worldwide. But as millions of patients begin — and eventually discontinue — these therapies, one critical question remains: What happens next? A new meta-analysis published in
Wegovy vs Tirzepatide: Real-World Study Shows Major Cardiovascular Advantage for Semaglutide
A new observational study highlights a striking difference in outcomes between two leading GLP-1 therapies in high-risk patients. As GLP-1 receptor agonists continue to redefine obesity treatment, emerging evidence suggests that not all GLP-1s are created equal—especially when it comes
What Happens After You Stop GLP-1 Therapy? The Rebound Risk
The rise of GLP-1 receptor agonists like semaglutide and tirzepatide has transformed obesity treatment worldwide. But as millions of patients begin — and eventually discontinue — these therapies, one critical question remains: What happens next? A new meta-analysis published in
What Happens After You Stop GLP-1 Therapy? The Rebound Risk
The rise of GLP-1 receptor agonists like semaglutide and tirzepatide has transformed obesity treatment worldwide. But as millions of patients begin — and eventually discontinue — these therapies, one critical question remains: What happens next? A new meta-analysis published in
Obesity R&D Is Booming. But Are We Ready for What Comes Next?
The global R&D landscape is shifting — and obesity is now at the center. According
Orforglipron vs Oral Semaglutide: What the Future of GLP-1 Could Look Like
The GLP-1 revolution is just getting started. While most people today associate GLP-1 medications with
GLP-1 and Muscle Loss: What You Need to Know
GLP-1 medications like semaglutide and tirzepatide have changed the way we treat obesity. But as
Improving GLP-1 Persistence: How Digital Therapeutics Can Help
GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) are transforming the treatment landscape
The Metabolic Window: A Unique Opportunity to Reset Your Habits with GLP-1
When patients start a GLP-1 therapy like semaglutide or tirzepatide, something important happens. Appetite decreases.
WHO Adds GLP-1 Therapies to Its Essential Medicines List: A Turning Point in Metabolic Health
The World Health Organization has just updated its Model List of Essential Medicines (EML), and
New Horizons for GLP-1 Medicines: Why Boli’s Path Is Only Just Starting
A recent article in JAMA, New Molecules and Indications for GLP-1 Medicines, explores what could
From Weight Loss to Heart Protection: New Evidence on GLP-1s
A landmark study published in JAMA (August 2025) shines a powerful light on what we
This JAMA Study Confirms What Boli Has Believed From the Start
In July 2025, JAMA published a pivotal article — Managing Adverse Effects of Incretin-Based Medications
Wegovy vs Tirzepatide: Real-World Study Shows Major Cardiovascular Advantage for Semaglutide
A new observational study highlights a striking difference in outcomes between two leading GLP-1 therapies